Free Trial
NASDAQ:FIXX

Homology Medicines (FIXX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.33
$16.82
52-Week Range
N/A
Volume
22,300 shs
Average Volume
390,307 shs
Market Capitalization
$978.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.75

Homology Medicines MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
∞ Upside
$0.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.75) to ($0.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.94 out of 5 stars

Medical Sector

640th out of 915 stocks

Pharmaceutical Preparations Industry

308th out of 435 stocks

FIXX stock logo

About Homology Medicines Stock (NASDAQ:FIXX)

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

FIXX Stock News Headlines

FIXX Homology Medicines, Inc.
Home To The World’s Largest High-Grade Uranium Deposits
Nuclear is one of the safest forms of energy around. In its entire history, nuclear is responsible for fewer deaths than oil and gas pollution cause every year. And investors are eyeing uranium exploration companies as one of the surest plays on the current nuclear renaissance.
Homology Medicines Inc (FIXX)
Home To The World’s Largest High-Grade Uranium Deposits
Nuclear is one of the safest forms of energy around. In its entire history, nuclear is responsible for fewer deaths than oil and gas pollution cause every year. And investors are eyeing uranium exploration companies as one of the surest plays on the current nuclear renaissance.
See More Headlines
Receive FIXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
7/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FIXX
Fax
N/A
Employees
7
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$0.75
High Stock Price Target
$0.75
Low Stock Price Target
$0.75
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-112,960,000.00
Net Margins
-4,779.31%
Pretax Margin
-7,532.87%

Debt

Sales & Book Value

Annual Sales
$1.16 million
Book Value
$1.26 per share

Miscellaneous

Free Float
48,774,000
Market Cap
$978.01 million
Optionable
Optionable
Beta
-0.10

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Paul Alloway J.D. (Age 52)
    Ph.D., President & COO
    Comp: $661.45k
  • Dr. Saswati Chatterjee Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Charles Michaud Jr.
    CPA, VP of Finance, Corporate Controller & Treasurer
  • Ms. Theresa McNeely (Age 60)
    Chief Communications Officer & Patient Advocate

FIXX Stock Analysis - Frequently Asked Questions

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) issued its earnings results on Monday, November, 15th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The company had revenue of $1.68 million for the quarter, compared to analyst estimates of $0.63 million. Homology Medicines had a negative trailing twelve-month return on equity of 102.52% and a negative net margin of 4,779.31%.

When did Homology Medicines' stock split?

Homology Medicines's stock split before market open on Wednesday, March 20th 2024. The 2-1 split was announced on Wednesday, March 20th 2024. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

When did Homology Medicines IPO?

Homology Medicines (FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC) and Dynavax Technologies (DVAX).

This page (NASDAQ:FIXX) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners